代謝性疾病生產線分析：異常血脂肪症、糖尿病、肥胖

本報告已在2011年07月19日停止出版。

簡介

目錄

Abstract

In This Issue...

Metabolic diseases affect millions of people worldwide. Thousands of metabolic diseases have been identified in humans, yet just a handful of these diseases account for the vast majority of the morbidity and mortality. The World Health Organization (WHO) estimates that type 2 diabetes affects 135 million people worldwide and that 300 million people meet the criteria for obesity. Dyslipidemia is another major metabolic disorder, affecting approximately 300 million people in the United States, Japan, and Western Europe.

Because these three disorders--type 2 diabetes, obesity, and dyslipidemia--are highly prevalent and lead to significant morbidity and mortality, they are the main focus of this report. We also discuss several metabolic disorders that are less severe but account for significant morbidity. These disorders include "metabolic syndrome" (which comprises several conditions), polycystic ovarian syndrome (PCOS), and non-alcoholic steatohepatitis (NASH). (We do not discuss hypertension, a common feature of metabolic syndrome, in this report because it is multifactorial in origin and not generally considered a metabolic disorder.)

Table of Contents

Executive Summary

• Which companies are the major players in the metabolic disease market?
• Which companies are the emerging players developing promising treatments for metabolic diseases?
• What is the commercial outlook for the metabolic disease market?

Chapter 1. Background of a Worldwide Epidemic

Chapter 2. Overview of Metabolic Diseases

• Type 2 Diabetes
• Obesity
• Dyslipidemia
• Metabolic Syndrome
• Non-Alcoholic Steatohepatitis
• Polycystic Ovarian Syndrome

Chapter 3. Current and Emerging Treatments for Metabolic Diseases

• Drugs Targeting Type 2 Diabetes
  • Insulin
    • Inhaled Insulin
    • Oral Insulin
  • Sulfonylurea Drugs
  • Meglitinides
  • Biguanides
  • Alpha-Glucosidase Inhibitors
  • PPAR Agonists (Thiazolidinediones)
  • Amylin Analogues
  • Incretin Mimetics
  • DPP-IV Inhibitors
  • SGLT2 Inhibitors
  • 11-Beta-HSD Type 1 Inhibitors
  • Beta-3 Adrenergic Agonists
• Drugs Targeting Obesity
  • Noradrenergic Anorectic Agents
  • Serotonin-Norepinephrine Reuptake Inhibitors. .
  • Lipase Inhibitors .
  • Melanin-Concentrating Hormone Receptor Antagonists .
  • Cannabinoid Antagonists
  • Neuropeptide Y Agonists
• Drugs Targeting Dyslipidemia
  • Statins (HMG-CoA Reductase Inhibitors) .
  • Fibric Acids
  • Bile Acid Sequestrants
  • Nicotinic Acid
  • Cholesterol Absorption Inhibitors .
  • Cholesteryl Ester Transferase Protein Inhibitors.
  • Squalene Synthase Inhibitors
  • Microsomal Triglyceride Transfer Protein Inhibitors
  • Acyl-CoA:Cholesterol Acyltransferase Inhibitors

Chapter 4. Company Profiles

• Abbott Laboratories
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Alizyme
  • Drugs in Development
• Amgen.
  • Drugs in Development
• Amylin Pharmaceuticals
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• AstraZeneca
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Bristol-Myers Squibb
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Eli Lilly
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• GlaxoSmithKline
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Isis Pharmaceuticals. .
  • Drugs in Development. .
• Ligand Pharmaceuticals .
  • Drugs in Development
• Merck & Co..
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Metabolex
  • Drugs in Development
• Novartis
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Novo Nordisk
  • Currently Marketed Drugs for Metabolic Disorders
• Pfizer
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Roche
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Sanofi-Aventis
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Schering-Plough
  • Currently Marketed Drugs for Metabolic Disorders

Chapter 5. Outlook for Metabolic Disease Therapeutics

Bibliography

相關商品

藥物開發相關市場調查報告書

乳癌，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Breast Cancer, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

大腸癌，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Colorectal Cancer, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

白血病，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Leukemia, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

Decision Resources, Inc.發行的製藥相關市場調查報告書

傳染病疫苗開發平台:競爭檢討

Special Report: The Infectious Disease Vaccine Pipeline--A Competitive Review

價格 : US $ 9200

出版日期 : 2011年06月

感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會

Special Report: Infectious Disease Vaccines--Unmet Needs and Opportunities for Pharma

價格 : US $ 9200

出版日期 : 2011年06月

自閉症譜系障礙:高未滿足需求創造出很大的市場機會

Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities

價格 : US $ 9200

出版日期 : 2011年06月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!